Abstract
Patients with psoriasis have an impaired quality of life and higher use of analgesics than the general population. Whether such use is due to skin pain or a consequence of joint pain resulting from psoriatic arthritis (PsA) is not clear. To assess symptoms, disease burden, and use of analgesics in patients with psoriasis with and without PsA. Symptoms, general health (EurQol 5-dimension and 5-levels), and use of analgesics were assessed in patients with psoriasis and the general population from the Danish Skin Cohort. We included 4016 patients with psoriasis (847 with concomitant PsA) and 3490 reference individuals. For patients with psoriasis having PsA, itch, skin pain, and/or joint pain was associated with worse general health. Use of opioids within 12months was observed among 9.0% of the general population, 14.2% of patients with psoriasis without PsA, and 22.7% of patients with concomitant PsA. Of the symptoms, only joint pain was associated with use of analgesics (odds ratio, 3.72 (2.69-5.14); P<.0001). Cross-sectional design. Patients with psoriasis (especially concomitant PsA) have a higher use of analgesics compared with the general population, which appears to be a result of increased joint pain.
Highlights
Psoriasis is a chronic immune-mediated inflammatory disease characterized by silvery scaly plaques affecting 2% to 4% of the world’s population,[1] and up to 8% to 11% of some Northern European countries.[2,3] The inflammation extends beyond the skin and often involves the joints
Pad Patients with psoriasis have a higher use of analgesics compared with the general population, which appear to be a result of increased joint pain
The proportion of patients reporting moderate-to-severe itch was 34% in those with psoriatic arthritis (PsA) and 30% in those without PsA (P = .022), moderate-to-severe skin pain was reported by 30% of those with PsA and 21% of those without PsA (P \ .0001), and moderate-to-severe joint pain was reported by 69% of those with PsA and 45% of those without PsA (P \.0001)
Summary
Psoriasis is a chronic immune-mediated inflammatory disease characterized by silvery scaly plaques affecting 2% to 4% of the world’s population,[1] and up to 8% to 11% of some Northern European countries.[2,3] The inflammation extends beyond the skin and often involves the joints. Bispebjerg and Frederiksberg Hospital, University of Copenhagend; and Department of Dermatology, Bispebjerg Hospital, Copenhagen.e. Patients with psoriasis have an impaired quality of life and higher use of analgesics than the general population. Patients with psoriasis have an impaired quality of life and higher use of analgesics than the general population Whether such use is due to skin pain or a consequence of joint pain resulting from psoriatic arthritis (PsA) is not clear
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
